Clareo Health | Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients 18-75 years of age
Kidney transplant 30-180 days post-transplantation
Receipt of cyclosporine or tacrolimus, CellCept, and corticosteroids for greater than 14 days prior to study entry
No known contraindications to sirolimus
You may not be if
Multiple organ transplant recipients or secondary kidney transplant recipients
Corticosteroid-resistant rejection episode within 90 days prior to study entry or corticosteroid-sensitive rejection episode within 30 days prior to study entry
More than 1 biopsy-proven episode of acute rejection prior to study entry
Treated with sirolimus before the study
Organ transplant or expected organ transplant, other than kidney
History of malignancy in the last 5 years (except successfully treated localized non-melanotic skin cancer)
